No Data
Shenzhen Chipscreen Biosciences Secures Clinical Trial Approval for Hepatitis B Drug; Shares Down 3%
2024 Annual Results Express Announcement
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Business Is Trailing The Industry But Its Shares Aren't
2024 Annual Results Forecast Announcement
Shenzhen Chipscreen Biosciences (688321.SH): Expected net loss of approximately 0.11 billion yuan in 2024.
Gelonghui, on January 17, announced that Shenzhen Chipscreen Biosciences (688321.SH) expects to achieve revenue of approximately 657.8468 million yuan for the fiscal year 2024, a year-on-year increase of about 25.61%. (2) The company expects to achieve a net income attributable to shareholders of listed companies of approximately -111.4337 million yuan for the fiscal year 2024, a decrease of about 200.2722 million yuan compared to the same period last year, which is a year-on-year decrease of approximately 225.43%. (3) The company expects to achieve a net income attributable to shareholders of listed companies, excluding non-recurring gains and losses of -20,290.1.
Shenzhen Chipscreen Biosciences (688321.SH): Some Shareholders no longer constitute a concerted action relationship.
On January 17, Gelonghui reported that Shenzhen Chipscreen Biosciences (688321.SH) announced it had received a "Notification Letter on the Termination of the Concerted Action Relationship" issued by the shareholders Shenzhen Haideruida Enterprise Management Partnership (Limited Partnership), Nam Cheong Haideruiyuan Enterprise Management Partnership (Limited Partnership) (referred to as "Haideruida" and "Haideruiyuan" respectively) and Dr. XIANPINGLU. Since the period specified in the "Concerted Action Agreement" signed by Haideruida, Haideruiyuan, and Dr. XIANPINGLU to maintain a concerted action relationship for 36 months after the company's public listing has expired, Haideruida and Haideruiyuan...
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 30% Share Price Surge Not Quite Adding Up
